Publications

Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlam J, Anderson J, Wisecarver J, Colcher D. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997. PMID: 9193348


Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1997. PMID: 9098192


Carroll PR, Presti JC, Small E, Roach M. Focal therapy for prostate cancer 1996: maximizing outcome. Urology. 1997. PMID: 9123742


De Marco T, Damon LE, Colombe B, Keith F, Chatterjee K, Garovoy MR. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 1997. PMID: 9087880


Tempero MA. Walking a difficult path is easier with a friend. Thoughts from a practicing oncologist. Annals of the New York Academy of Sciences. 1997. PMID: 9103574


Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997. PMID: 9053511


Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997. PMID: 9053511


Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, Colcher D. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. Journal of clinical immunology. 1997. PMID: 9049790


Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997. PMID: 8996165


Bullard KM, Banda MJ, Arbeit JM, Bergsland E, Young DM. Human acellular dermal matrix as a novel model of malignant epithelial cell invasion. Invasion & metastasis. 1997. PMID: 9425323


Venook AP. Can a vitamin prevent hepatocellular carcinoma? Hepatology (Baltimore, Md.). 1997. PMID: 8985300


Small EJ, Dawson NA, Kantoff PW, Vogelzang NJ. Cancer and Leukemia Group B trials for advanced prostate cancer. Seminars in oncology. 1996. PMID: 8996582


Ogawa S, Gordan JD, Taylor J, Lubahn D, Korach K, Pfaff DW. Reproductive functions illustrating direct and indirect effects of genes on behavior. Hormones and behavior. 1996. PMID: 9047273


Engstrom PF, Benson AB, Cohen A, Doroshow J, Kiel K, Niederhuber J, Roh M, Tempero M. NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park, N.Y.). 1996. PMID: 8953601


Komanduri KV, Luce JA, McGrath MS, Herndier BG, Ng VL. The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association. 1996. PMID: 8898666


Roach M, Meehan S, Kroll S, Weil M, Ryu J, Small EJ, Margolis LW, Presti J, Carroll PC, Phillips TL. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. The Journal of urology. 1996. PMID: 8863578